IMV, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm's patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorHealth Technology
CIKN/A
WebN/A
Phone(902) 492-1819
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date3/19/2020 (Estimated)
OptionableNot Optionable
IMV (NYSE:IMV) Frequently Asked Questions
What is IMV's stock symbol?
IMV trades on the New York Stock Exchange (NYSE) under the ticker symbol "IMV."
How were IMV's earnings last quarter?
Imv Inc (NYSE:IMV) announced its quarterly earnings results on Friday, November, 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by $0.03. The firm had revenue of $0.12 million for the quarter, compared to analysts' expectations of $0.05 million. View IMV's Earnings History.
When is IMV's next earnings date?
What price target have analysts set for IMV?
7 brokerages have issued twelve-month target prices for IMV's stock. Their forecasts range from $6.00 to $12.25. On average, they expect IMV's stock price to reach $9.79 in the next year. This suggests a possible upside of 104.8% from the stock's current price. View Analyst Price Targets for IMV.
What is the consensus analysts' recommendation for IMV?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMV in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IMV.
What are Wall Street analysts saying about IMV stock?
Here are some recent quotes from research analysts about IMV stock:
- 1. According to Zacks Investment Research, "IMV Inc. is a clinical-stage immuno-oncology company. Its proprietary drug development platform provides a patented delivery formulation which enables controlled and prolonged exposure of antigens to the immune system. The company's pipeline consists of DPX-Survivac, DPX-E7 and DPX-RSV which are in clinical stage. IMV Inc. is based in Halifax, Canada. " (11/13/2019)
- 2. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $11.50 price target. Our valuation is based on our clinical net present value (NPV) model, which allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Our valuation is currently based on the opportunities in the U.S. for only DPX-Survivac, the leading asset, in ovarian cancer (approximately 43% valuation contribution, 30% chance of success), DLBCL (15% valuation contribution, 15% chance of success), and the indications in the basket trial (41% valuation contribution, 10% chance of success)." (6/12/2019)
Has IMV been receiving favorable news coverage?
News stories about IMV stock have trended very negative recently, according to InfoTrie. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. IMV earned a media sentiment score of -3.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for IMV.
Who are some of IMV's key competitors?
Some companies that are related to IMV include BELLUS Health (BLU), Paradigm Biopharmaceuticals (PAR), CEL-SCI (CVM), Cel-Sci (CVM), Oxford BioMedica (OXB), Bellus Health (BLU), Starpharma (SPL), Pfenex (PFNX), Pfenex (PFNX), TELIX Pharmaceutical (TLX), Trillium Therapeutics (TRIL), Biotest (BIO), Silence Therapeutics (SLN), Rafael (RFL) and ProMetic Life Sciences (PLI).
What other stocks do shareholders of IMV own?
Who are IMV's key executives?
IMV's management team includes the folowing people:
- Frederic Ors, CEO, Director & Chief Business Officer
- Pierre Labbé, Chief Financial Officer
- Gabriela Nicola Rosu, Chief Medical Officer
- Marianne Stanford, Vice President-Research
- Joseph Sullivan, Senior Vice President-Business Development
Who are IMV's major shareholders?
IMV's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FIL Ltd (4.84%), Bank of Montreal Can (0.21%), Guardian Capital Advisors LP (0.16%) and First City Capital Management Inc. (0.06%).
Which institutional investors are selling IMV stock?
IMV stock was sold by a variety of institutional investors in the last quarter, including FIL Ltd and Guardian Capital Advisors LP.
Which institutional investors are buying IMV stock?
IMV stock was bought by a variety of institutional investors in the last quarter, including First City Capital Management Inc. and Bank of Montreal Can.
How do I buy shares of IMV?
Shares of IMV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is IMV's stock price today?
One share of IMV stock can currently be purchased for approximately $4.78.
How big of a company is IMV?
How can I contact IMV?
The company can be reached via phone at (902) 492-1819.
MarketBeat Community Rating for IMV (NYSE IMV)
MarketBeat's community ratings are surveys of what our community members think about IMV and other stocks. Vote "Outperform" if you believe IMV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMV will underperform the S&P 500 over the long term. You may vote once every thirty days.
